Home・Aandelen Lijst・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Gesloten

SectorGezondheidszorg

13.25 3.27

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.53

Max

13.62

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.2M -13M
Verkoop	-1.5M 17M
EPS	-0.45
Winstmarge	-76.292
Werknemers	120
EBITDA	-958K -8.6M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+54.44% upside

Dividenden
By Acuity
Volgende Winsten	7 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-52M 370M
Vorige openingsprijs	9.98
Vorige sluitingsprijs	13.25

Nieuwssentiment

By Acuity

31%

69%

97 / 340 Rangschikking in Healthcare

ENANTA PHARMACEUTICALS INC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 19:23 UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

31 jul 2026, 20:06 UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

30 jul 2026, 19:45 UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

29 jul 2026, 18:26 UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

28 jul 2026, 20:06 UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

27 jul 2026, 18:36 UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

24 jul 2026, 20:06 UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

21 jul 2026, 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20 jul 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Peer Vergelijking

Prijswijziging

ENANTA PHARMACEUTICALS INC Prognose

Koersdoel

By TipRanks

54.44% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20 USD 54.44%

Hoogste 20 USD

Laagste 20 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor ENANTA PHARMACEUTICALS INC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan ENANTA PHARMACEUTICALS INC - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

97 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.